Research Analysts Set Expectations for LPTX FY2029 Earnings

Leap Therapeutics, Inc. (NASDAQ:LPTX) – Analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Leap Therapeutics in a research report issued on Wednesday, January 29th. HC Wainwright analyst S. Ramakanth forecasts that the company will earn ($0.29) per share for the year. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Leap Therapeutics’ current full-year earnings is ($1.84) per share.

Other research analysts also recently issued reports about the stock. Baird R W downgraded shares of Leap Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. Robert W. Baird downgraded Leap Therapeutics from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $9.00 to $1.25 in a report on Wednesday.

Leap Therapeutics Stock Down 12.1 %

LPTX stock opened at $0.57 on Thursday. Leap Therapeutics has a 52 week low of $0.55 and a 52 week high of $4.79. The business has a fifty day simple moving average of $2.82 and a 200-day simple moving average of $2.75. The company has a market cap of $21.90 million, a price-to-earnings ratio of -0.30 and a beta of 0.17.

Hedge Funds Weigh In On Leap Therapeutics

Several large investors have recently made changes to their positions in the business. Valence8 US LP purchased a new position in Leap Therapeutics in the 3rd quarter worth about $48,000. HighTower Advisors LLC acquired a new position in shares of Leap Therapeutics in the third quarter worth about $65,000. HB Wealth Management LLC increased its position in shares of Leap Therapeutics by 103.2% in the fourth quarter. HB Wealth Management LLC now owns 51,500 shares of the company’s stock worth $150,000 after acquiring an additional 26,150 shares in the last quarter. Key Client Fiduciary Advisors LLC raised its holdings in shares of Leap Therapeutics by 13.0% during the third quarter. Key Client Fiduciary Advisors LLC now owns 321,923 shares of the company’s stock valued at $827,000 after acquiring an additional 37,067 shares during the period. Finally, Geode Capital Management LLC raised its holdings in shares of Leap Therapeutics by 18.0% during the third quarter. Geode Capital Management LLC now owns 329,291 shares of the company’s stock valued at $847,000 after acquiring an additional 50,194 shares during the period. Institutional investors own 30.46% of the company’s stock.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.